By Matthew Guarnaccia ( September 14, 2018, 7:08 PM EDT) -- Cooley LLP-guided immuno-oncology firm Allogene Therapeutics on Friday unveiled a $100 million initial public offering in a bid to push ahead with its allogeneic T cell cancer therapies, while fellow biopharmaceutical company Arvinas Holding Co. LLC priced its own offering of $100 million at midpoint, with WilmerHale leading the way....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.